Left ventricular assist devices decrease fixed pulmonary hypertension in cardiac transplant candidates

Zimpfer, Daniel; Zrunek, Philipp; Roethy, Wilfried; Czerny, Martin; Schima, Heinrich; Huber, Leopold; Grimm, Michael; Rajek, Angela; Wolner, Ernst; Wieselthaler, Georg

doi:10.1016/j.jtcvs.2006.08.104

Cited by 168 publications

(112 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Heterotopic cardiac transplantation and reversing of fixed pulmonary hypertension using ventricular assist devices prior to cardiac transplantation have been reported to be successful treatment options in these patients [3][4][5][6][7]. However, heterotopic cardiac transplantation is associated with a variety of adverse effects in the long run (arrhythmias, thromboembolism) [3,8,9].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Post-transplant survival after lowering fixed pulmonary hypertension using left ventricular assist devices

Zimpfer

Zrunek

Sandner

et al. 2007

European Journal of Cardio-Thoracic Surgery

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…We have previously reported our experience with reversal of fixed pulmonary hypertension in cardiac transplant candidates using ventricular assist devices [7].…”

Section: Introductionmentioning

confidence: 99%

Post-transplant survival after lowering fixed pulmonary hypertension using left ventricular assist devices

Zimpfer

Zrunek

Sandner

et al. 2007

European Journal of Cardio-Thoracic Surgery

Self Cite

View full text Add to dashboard Cite

show abstract

“…Ultimately, 69% were successfully bridged to transplantation. Improvement in PVR occurred fairly quickly with a reduction in mean PVR from 5.1±2.7 WU (baseline) to 2.9±1.3 WU (at 3 days) and to 2.0±0.8 WU at 6 weeks [43].…”

Section: Right Heart Failurementioning

confidence: 89%

Ventricular Assist Devices: History, Patient Selection, and Timing of Therapy

Tang

Oyer

Mallidi

2009

J. of Cardiovasc. Trans. Res.

View full text Add to dashboard Cite

Timing of therapy and selection of patients in the use of ventricular assist devices (VADs) can be difficult. In general, consideration for VAD implantation is appropriate in patients with endstage heart failure who are failing optimal medical therapy and in whom no alternative traditional surgical treatment options are available. However, identifying when a particular patient has reached this point is not always straightforward. There are a broad range of medical and surgical therapies for patients with overt heart failure, and this armamentarium is constantly expanding. The risks, benefits, and expected outcomes with VAD therapy have also undergone dramatic changes over the last decade. Advances in technology have led to a proliferation of newer generation devices that are smaller, lighter, easier to implant, and more reliable than previous generation devices. This, in turn, has led to a markedly improved risk-benefit ratio, with increased durability and reduced morbidity. The indications for the implantation of ventricular assist devices have also evolved over the last several years, and specific patient presentations and goals of therapy have led to specific indications. Device therapy has traditionally been classified as bridge to recovery, bridge to transplantation, and destination therapy. However, such designations may not be well defined at the time of implantation, and recovery and response following initiation of VAD support may allow patients to change from one classification to another. The current data regarding indications and timing of device implantation are reviewed.

show abstract

“…The reversibility of the pulmonary hypertension was confirmed with the use of nitroglycerin, at doses between 2 to 6 mg/ h, which was administered intravenously. Pulmonary hypertension is considered fixed when the PVR does not fall, at least, less than 20% of the baseline after the test with the vasodilator [8].…”

Section: Right Heart Catheterizationmentioning

confidence: 99%

Pressão pulmonar aferida pela ecocardiografia em pacientes chagásicos indicados para transplante cardíaco

Gelape¹,

C²,

Braulio³

et al. 2011

Rev Bras Cir Cardiovasc

View full text Add to dashboard Cite

Left ventricular assist devices decrease fixed pulmonary hypertension in cardiac transplant candidates

Cited by 168 publications

References 33 publications

Post-transplant survival after lowering fixed pulmonary hypertension using left ventricular assist devices

Post-transplant survival after lowering fixed pulmonary hypertension using left ventricular assist devices

Ventricular Assist Devices: History, Patient Selection, and Timing of Therapy

Pressão pulmonar aferida pela ecocardiografia em pacientes chagásicos indicados para transplante cardíaco

Contact Info

Product

Resources

About